"The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.
No proven antidotes have been established for ETOPOPHOS (etoposide phosphate) overdosage in humans. In mice, a single intravenous dose of rapidly administered ETOPOPHOS (etoposide phosphate) was lethal at or above 120 mg/kg (about 7 times human dose on a mg/m² basis) and was associated with clinical signs of neurotoxicity.
ETOPOPHOS (etoposide phosphate) for Injection is contraindicated in patients who have demonstrated a previous hypersensitivity to etoposide, etoposide phosphate, or any other component of the formulations.
Last reviewed on RxList: 5/12/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Etopophos Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.